JP2016510315A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510315A5
JP2016510315A5 JP2015548630A JP2015548630A JP2016510315A5 JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5 JP 2015548630 A JP2015548630 A JP 2015548630A JP 2015548630 A JP2015548630 A JP 2015548630A JP 2016510315 A5 JP2016510315 A5 JP 2016510315A5
Authority
JP
Japan
Prior art keywords
combination
combination according
tissue factor
fusion protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548630A
Other languages
English (en)
Japanese (ja)
Other versions
JP6518591B2 (ja
JP2016510315A (ja
Filing date
Publication date
Priority claimed from EP12198839.8A external-priority patent/EP2745852A1/en
Application filed filed Critical
Publication of JP2016510315A publication Critical patent/JP2016510315A/ja
Publication of JP2016510315A5 publication Critical patent/JP2016510315A5/ja
Application granted granted Critical
Publication of JP6518591B2 publication Critical patent/JP6518591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548630A 2012-12-21 2013-12-20 シーラント組成物 Expired - Fee Related JP6518591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12198839.8 2012-12-21
EP12198839.8A EP2745852A1 (en) 2012-12-21 2012-12-21 Sealant compositions
PCT/EP2013/077674 WO2014096354A1 (en) 2012-12-21 2013-12-20 Sealant compositions

Publications (3)

Publication Number Publication Date
JP2016510315A JP2016510315A (ja) 2016-04-07
JP2016510315A5 true JP2016510315A5 (https=) 2017-02-09
JP6518591B2 JP6518591B2 (ja) 2019-05-22

Family

ID=47563088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548630A Expired - Fee Related JP6518591B2 (ja) 2012-12-21 2013-12-20 シーラント組成物

Country Status (17)

Country Link
US (1) US20160082145A1 (https=)
EP (2) EP2745852A1 (https=)
JP (1) JP6518591B2 (https=)
CN (1) CN104955493A (https=)
AU (1) AU2013366544B2 (https=)
BR (1) BR112015014926B1 (https=)
CY (1) CY1118938T1 (https=)
DK (1) DK2934612T3 (https=)
ES (1) ES2627053T3 (https=)
HR (1) HRP20170880T1 (https=)
HU (1) HUE034649T2 (https=)
LT (1) LT2934612T (https=)
MX (1) MX361222B (https=)
PL (1) PL2934612T3 (https=)
PT (1) PT2934612T (https=)
SI (1) SI2934612T1 (https=)
WO (1) WO2014096354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010906B (zh) * 2018-08-16 2021-05-14 陈明远 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法
US11666682B2 (en) * 2020-08-31 2023-06-06 Ethicon, Inc. Method of stopping CSF leaks and apparatus therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748215B1 (en) * 1994-02-17 2003-05-28 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
EP0885020A1 (en) * 1996-02-20 1998-12-23 Cohesion Corporation Tissue sealant compositions and methods of use thereof
AU9786198A (en) * 1997-10-10 1999-05-03 University Of Virginia Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
EP1939218A1 (en) 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP2145695A1 (de) 2008-07-14 2010-01-20 Sika Technology AG Vorrichtung zur Klebstoffapplikation
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof

Similar Documents

Publication Publication Date Title
WO2017100700A3 (en) Peptides for renal therapy
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
HK1207097A1 (en) Fusion proteins for treating a metabolic syndrome
WO2014150600A3 (en) Modified toxins
NZ603200A (en) Peptides and their use
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
EP4488289A3 (en) Long-acting coagulation factors and uses thereof
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2014150375A3 (en) Treatment of collagen defects using protein solutions
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
HK1216617A1 (zh) 用人生长激素类似物治疗小儿生长激素缺乏症
EP2924049A4 (en) TROPHIC HORMONFUSION PROTEIN, METHOD OF MANUFACTURE AND APPLICATION THEREOF
EA201691008A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
EP4275751A3 (en) Improved naglu fusion protein formulation
JP2010538020A5 (https=)
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.